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Background: Chimeric Antigen Receptors (CARs) consist of the antigen-recognition portion of a monoclonal
antibody fused to an intracellular signaling domain capable of activating T-cells. CARs displayed on the surface of
transduced cells perform non-MHC-restricted antigen recognition and activating intracellular signaling pathways for
induction of target cytolysis, cytokine secretion and proliferation. Clinical trials are in progress assessing the use of
mature T-lymphocytes transduced with CARs targeting CD19 antigen to treat B-lineage malignancies. CD19 is an
attractive target for immunotherapy because of its consistent and specific expression in most of the stages of
maturation and malignancies of B-lymphocyte origin, but not on hematopoietic stem cells. Antibodies against the
extracellular domain of the CAR molecule (anti-Fab, Fc or idiotype) have been used for detection of CAR expression
in research and clinical samples by flow cytometry, but may need development for each construct and present
significant background in samples from xenograft models.
Methods: A specific reagent for the detection of anti-CD19 CAR expression was developed, a fusion protein
consisting of human CD19 extracellular domains and the Fc region of human IgG1 (CD19sIg). Genes encoding
CD19sIg fusion proteins were constructed by fusing either exons 1 to 3 (CD19sIg1-3) or exons 1 to 4 (CD19sIg1-4)
of the human CD19 cDNA to a human IgG1Fc fragment. These fusion proteins are intended to work in similar
fashion as the MHC Tetramers used for identification of antigen-specific T-cells, and may also have other
applications in studies of activation of anti-CD19 CAR bearing cells. The CD19sIg proteins were produced from
293 T cells by stable lentiviral vector transduction and purification from culture medium.
Results: ELISA assays using several different monoclonal antibodies to CD19 demonstrated dose-related specific
binding by the fusion molecule CD19sIg1-4, but no binding by CD19sIg1-3. Conjugation of the CD19sIg1-4 fusion
protein to Alexa Fluor 488 allowed specific and sensitive staining of anti-CD19 CAR-bearing cells for flow cytometry
assays, detecting as low as 0.5% of CAR-modified primary cells with minimal background staining.
Conclusions: This fusion molecule is a sensitive reagent for detection of anti-CD19 CAR derived from any
monoclonal antibody present in CAR-modified T-cells.
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Chimeric Antigen Receptors (CARs) have been used over
the last twenty years to redirect specificity of T-cells for
use in immunotherapy research approaches. Among mul-
tiple targeted antigens, CD19 has been increasingly studied
for its expression in most of the B lineage hematological
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distribution, and reproduction in any mediumusing adoptive transfer of T-cells armed with CD19-
specific CAR. The same approach is currently being evalu-
ated in clinical trials with initial success reported [1].
Detection of CAR-bearing cells has usually been
performed by flow cytometry, with the use of antibodies
against the extracellular structure of the molecule, such as
the hinge (using an anti-IgG Fc antibody or F(ab’)2 frag-
ment) or the antigen-binding domains (as in the case of
the use of an anti-idiotypic antibody). More recently, pro-
tein L isolated from Peptostreptococcus was proposed for
detection of CAR expression by flow cytometry [2]. Usingtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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specific reagent for the detection of the CD19-specific
CAR, we developed a CD19/Fc molecule that can be la-
beled for its use primarily as a reagent in flow cytometry
studies. Our approach consisted of fusing the extracellular
domains of the human CD19 protein [3-5] to the human
immunoglobulin Fc domain. Fusion to the Fc domain has
been used to allow secretion of peptide sequences, with en-
hanced solubility and stability, and a fusion protein of mur-
ine extracellular CD19 and Fc domain has been previously
described [6].
We describe the studies for the development and evalu-
ation of this fusion protein. The properties of this reagent
make possible sensitive detection by flow cytometry of
cells modified with CD19-specific CAR.
Material and methods
Construction of CD19-IgG1Fc expressing plasmids
The CD19-IgG1Fc fusion proteins, CD19sIg1-3 and
CD19sIg1-4, were constructed by fusing either exons 1 to 3
(E13) or exons 1 to 4 (E14) of the human CD19 cDNA
(Origene, Rockville, MD) to a human IgG1Fc (Fc) fragment
[7] by PCR-based cloning. Exons 1 through 3 of hCD19
were amplified using primers UNF (5’-CTGGCTAGCGTT
TAAACGGG-3’) and X3R (5’-CTGGCTGAGGCTCTGG
TTC-3’). Exons 1 through 4 of hCD19 of hCD19 were
amplified using primers UNF and X4R (5’- TGGCCGA
GCAGTGATCTC-3’). The IgG1Fc region was amplified
using a 5’phosphorylated primer FCF (5’- TCTGCAGA
GCCCAAATCTTG-3’) and the reverse primer ERFC
(5’- GTCCAGTGTGGTGGAATTCG -3’). The hCD19
PCR products were digested with EcoR1 and the IgG1Fc
product was digested with EcoR1. The digested products
were ligated into the Fc fragment-containing expression
plasmid (pCMV-Fc), previously digested with NheI and
EcoR1 to create either pCMV-CD19sIg1-3 or pCMV-
CD19sIg1-4. The CD19sIg1-3 and CD19sIg1-4 fragments
were then removed from the pCMV-CD19sIg1-3 and
pCMV- CD19sIg1-4 expression vectors by restriction en-
zyme digestion with EcoRI and XhoI. The lentiviral plas-
mid pCCLc-EFS-hADA-WPRE (from Adrian Thrasher,
University College London, London, UK) contains the
short human EF1a promoter [8] and the ADA (adenosine
deaminase) transgene. ADA was removed by BamH1 di-
gestion and the backbone religated to make pCCLc-EFS-X-
WPRE. The CD19sIg1-3 and CD19sIg1-4 fragments were
then cloned into the EcoRI/XhoI site of the pCCLc-EFS-X-
WPRE plasmid to make pCCLc-EFS-CD19sIg1-3-
WPRE and pCCLc-EFS-CD19sIg1-4-WPRE.
Cell culture
293 T cells (ATCC CRL-1268) were cultured in D10:
Dulbecco’s modified Eagle’s Medium (DMEM, Mediatech,
Herndon, VA) containing 10% fetal bovine serum (OmegaScientific, Tarzana, CA), 50 U/ml penicillin, 50 μg/ml
streptomycin, and 2 mM L-glutamine (Gemini Bio-
products, Woodland, CA). Jurkat cells (ATCC TIB-152)
and Raji cells (ATCC CCL-86) were cultured in R10:
RPMI medium (Irvine Scientific, Santa Ana, CA) con-
taining 10% fetal bovine serum, 50 U/ml penicillin, 50 μg/
ml streptomycin, and 2 mM L-glutamine.
Primary human cells
Human peripheral blood mononuclear cells (PBMC) were
obtained from anonymous donor blood samples (through
the UCLA CFAR Virology Core Laboratory) and isolated
using gradient centrifugation on Ficoll-Hypaque. T-
lymphocytes were activated with Dynabeads T-activator
CD3/CD28 (Invitrogen, Carlsbad, CA) in RPMI medium
containing 10% fetal bovine serum (Omega Scientific,
Tarzana, CA), 50 U/ml penicillin, 50 μg/ml streptomycin,
and 2 mM L-glutamine (Gemini Bioproducts, West Sacra-
ment, CA) (R10 medium) in an incubator at 37°C and 5%
CO2. After 72 hours of stimulation, the cells were washed
to remove the beads and immediately used for lentiviral
transduction, performed without prestimulation or supple-
mental cytokines in R10 medium, at a vector concentration
of 5 × 107 TU/ml. T-lymphocyte cultures were maintained
in R10 medium with recombinant human IL- 2 (10 ng/ml)
for a minimum of seven days before performing assays. All
cultures were tested for T-cell enrichment, and experi-
ments were performed only with populations consisting of
at least 85% of CD3-positive cells.
Primary murine cells
Mouse care and experiments followed protocols ap-
proved by the Animal Research Committee at UCLA.
For the development of xenografted NSG mice, pups
from the strain NOD/SCID/γcNull (NSG) were engrafted
with human cells through injection of 2 × 105 CD34(+)
human stem/progenitor cells (HSPC) after sub-lethal ir-
radiation (150 rads). Bone marrow from engrafted mice
(humanized NSG marrow) and control mice (NSG mar-
row) was harvested at 14 weeks of age for use in flow cy-
tometry studies.
Lentiviral vector production
The HIV-1 based lentiviral vectors, CCLc-EFS-CD19sIg1-3-
WPRE and CCLc-EFS-CD19sIg1-4-WPRE were produced
by triple-plasmid transfection of 5 μg of pCCLc-EFS-
CD19sIg1-3-WPRE or pCCLc-EFS-CD19sIg1-4-WPRE
plasmid, 5 μg of gag/pol expressing plasmid (pCMVΔR8.91)
[9], and 1 μg of the envelope expression plasmid pMD.G
(VSV) [10]. The 293 T cells were plated on poly-L-lysine-
coated 10-cm plates at 5 × 106 cells per plate in DMEM
with 10% FBS (D10) and transfection was performed 24 -
hours later using the standard TransIT-293 protocol
(Mirus Bio, Madison, WI.). Transfected cells were then
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(Sigma-Aldrich, St. Louis, MO.) and 20 mM HEPES in
D10. After 8–12 hr, the cells were rinsed once with PBS
and then fresh D10 with 20 mM HEPES was added. Vec-
tor containing supernatant was harvested 48 hours later.Concentration, purification and quantification of the
fusion protein
For transient expression of CD19-IgG1Fc fusion proteins;
1×105 293 T cells were transfected using the standard
manufacturer’s TransIT-293 protocol with 1 μg of pCMV-
CD19-IgG1Fc plasmid or pCCL-CD19-IgG1Fc-WPRE plas-
mid in 6-well tissue culture plates containing 1 ml of D10
medium. The cells were kept in transfection medium for
24 hours and then cultured in 3 ml of Pro293a™-CDM
serum-free medium (LONZA, Basel, Switzerland) con-
taining 2 mM L-glutamine, and then harvested. Stably
transduced 293 T cells were seeded in triple-layer flasks
(NUNC, Rochester, NY) with 150 ml of normal D10
medium. The medium was changed to 150 ml of
Pro293a™-CDM serum-free medium containing 2 mM L-
glutamine, when the cells reached confluence. After 2 days,
culture medium was harvested and concentrated using
Centricon Plus-70 (30 kDa cut-off) centrifugal filter de-
vices (Millipore, Billerica, MA.). Cell lysates were made
using NP40 cell lysis buffer (Invitrogen, Carlsbad, CA.).
Protease inhibitor cocktail, EDTA free (Thermo Scientific,
Waltham, MA) was added to protein samples (supernatant
or lysates) right after harvest to prevent degradation.
Harvested protein samples were purified using Dynabeads
Protein A Immunoprecipitation Kit (Invitrogen, Carlsbad,
CA.) according to the manufacturer’s instructions. Elution
of the CD19-IgG1Fc fusion was performed under denatur-
ing or non-denaturing (native) conditions according to the
manufacturer’s instructions. Purified protein samples were
quantified by using the Bicinchoninic acid (BCA) assay
(Thermo Scientific, Waltham, MA.), using bovine gamma
globulin (BGG) for the standard curve.SDS PAGE
Non-denaturing protein electrophoresis was performed
running 1 μg of each purified protein sample; reducing
conditions were performed mixing each purified sample
with 1 μl of Sample Reducing Agent (Invitrogen, Carlsbad,
CA.) and heating at 70°C for 10 min before electrophor-
esis on NuPAGE 4-12% Bis-Tris Mini Gels 1.0 mm
(Invitrogen, Carlsbad, CA.). The bands were visualized
by SimplyBlue™ SafeStain (Invitrogen, Carlsbad, CA.)
staining, and the gel was dried using DryEase Mini-Gel
Drying System (Invitrogen, Carlsbad, CA.). All proce-
dures were performed according to the manufacturer’s
instructions.Conjugation of the fusion protein
Purified fusion protein (15–20 μg) was conjugated by
using the Alexa Fluor 488 APEX™ Antibody Labeling
Kit (Invitrogen, Carlsbad, CA.), according to the manu-
facturer’s instructions.
Enzyme-linked immunosorbent assay (ELISA)
Flat-bottomed 96-well plates with a MaxiSorp surface
(NUNC, Rochester, NY.) were coated with 100 μL of
10 μg/ml capture antibodies for 1 hour at room
temperature. The plates were washed five times with
200 μl phosphate buffered saline with 0.05% Tween-20
(PBST) and then blocked in 300 μl of 5% bovine serum
albumin (BSA) (Sigma, St. Louis, MO.) for 1 hour at
room temperature. After five washes with PBST, the
plates were incubated for 2 h at room temperature with
200 μl of the CD19sIg1-3 or CD19sIg1-4 fusion protein
diluted in PBS. Following five washes with PBST, the
plates were incubated for 1 hour at room temperature
with 100 μl of alkaline phosphatase (AP)-conjugated de-
tection antibodies. Finally, the plates were washed five
times with PBST before being developed for 30 minutes
at room temperature with 100 μl of a p-Nitrophenyl-
phosphate (pNPP) substrate (Sigma, St. Louis, MO.) and
stopped by equal volume of 0.75 M NaOH. The stopped
reactions were assayed by spectrophotometry at 405 nm.
Capture antibodies used included goat anti-human IgG
Fc polyclonal antibody (Millipore, Billerica, MA.); Mouse
anti-human CD19 monoclonal antibodies including:
FMC63 (Millipore, Billerica, MA.), 2E2B6B10 (Abcam,
Cambridge, MA.), and F-3 (Santa Cruz Biotechnology,
Santa Cruz, CA.) and HIB19 (BD Biosciences, San Jose,
CA); Mouse anti-human CD20 B9E9 (Santa Cruz Bio-
technology, Santa Cruz, CA); and Mouse anti-human
PSMA (Prostate-Specific Membrane Antigen) YPSMA-1
(Abcam, Cambridge, MA.). The detection antibody used
was goat anti-human IgG Fc polyclonal antibody AP
(Millipore, Billerica, MA) (1:5000).
Flow cytometry
Transduced Jurkat cells and primary T-cells expressing
the anti-CD19 CAR were detected in mixed samples by
incubating 2×105 cells with 450 ng of the labeled fusion
protein at 4°C for 30 minutes in the dark, after being
blocked by human serum from AB plasma (Sigma-
Aldrich) for 10 minutes. After being washed two times
with PBS, cells were analyzed on a LSR II (BD Biosci-
ences, San Jose, CA.) machine running the FACSDiva™
software (BD Biosciences, San Jose, CA.). Similar staining
protocol was used for the commercially available CD19-Fc
fusion protein, rhCD19-Fc (ACROBiosystems, Bethesda,
MD.). Staining with biotinylated Protein L (GenScript,
Piscataway, NJ.) was performed immediately after the
blocking procedure following manufacturer instructions,
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Streptavidin (Sigma). For all tests, FITC-conjugated F(ab’)2
fragment goat anti-human IgG1 Fcγ (Jackson Immuno-
Research Laboratories, West Grove, PA.) (55.5 ng per 105
cells) was used as the positive control for the detection of
anti-CD19 CAR positive cells, after incubation of the cell
samples in 5% FBS for 10 minutes.
CD19-specific blocking experiments were performed
incubating labeled CD19sIg1-4 fusion protein with
FMC63 for 1 hour at 4°C before being added to the cells
for staining, at concentrations described in the results
section. The staining conditions after pretreatment were
kept 450 ng of Alexa Fluor 488-labeled CD19sIg1-4 for
2×105 cells.
Results
Construction of CD19-IgG1Fc expressing plasmids and
lentiviral vector production
The extracellular domain for human CD19 protein con-
















Figure 1 Construction and characterization of the CD19-IgG1Fc fusion
used to transduce the CD19sIg fusion genes. B. Reduced protein elect
concentration and purification using Protein A Dynabeads. Centricon c
(A), 293 T cells (B), 293 T cells expressing CD19sIg1-3 (C), and 293 T cells exp
CD19sIg1-3 and CD19sIg1-4 (respectively). Arrows indicate the predicted size
samples were reduced prior to loading. C. Native protein electrophoresis of C
Dynabeads; arrow points to 171 kDa band (expected size for trimers of the fu
capture antibody, of purified fusion proteins, in native (N) or denatured (D) fo
(FMC63, HIB19, F-3 and 2E2B6B10), human CD20 (B9E9) and PSMA (YPSMA-1)the exons 1 through 4 [3-5]. The fusion proteins
containing the CD19 extracellular domain were designed
in two versions, fusing exons 1–3 (CD19sIg1-3) and exons
1–4 (CD19sIg1-4), to human IgG1 fragment (Figure 1A);
this strategy was chosen as previously published data sug-
gested that the addition of exon 4 decreased protein secre-
tion (deFougerolles et al., 2001). The fusion fragments
were cloned into the pCCL lentiviral backbone driven by
the EFS promoter (Figure 1A).
Establishment of producer cell line
Lentiviral vectors were packaged and then used for stable
transduction of 293 T cells. Clones were selected by highest
level of production of fusion proteins assayed by ELISA.
The best-transduced clones produced approximately
double the amount of fusion protein (35.49 μg/ml of super-
natant of CD19sIg1-3 and 16.91 μg/ml of CD19sIg1-4)
yielded by transiently transfected 293 T cells (17.99 and
10.78 μg/ml of supernatant). Cell lysates had fusion protein












proteins. A. Diagrams of the lentiviral vector provirus constructs
rophoresis by SDS PAGE of fusion protein products after
oncentrated supernatant samples from fresh Pro293a™-CDM
ressing CD19sIg1-4 (D). Lanes E and F are the DYNAL purified extracts for
of the monomer, 47 kDa for CD19sIg1-3 and 57 kDa for CD19sIg1-4. All
D19sIg1-4 after concentration and purification using Protein A
sion protein). D. Results of a comparative ELISA using FMC63 monoclonal
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Detection of 5% anti-CD19 CAR-transduced human T-cells mixed with NSG bone marrow
























Figure 2 Evaluation of CD19sIg1-4 fusion protein on primary human cell populations. Flow cytometry plots using FITC-conjugated anti-IgG
Fc F(ab’)2 fragment (FITC-anti-IgG Fc, left panels) or Alexa Fluor 488-labeled CD19sIg1-4 (AF488-CD19sIg1-4, right panels) for detection of 5% anti-
CD19 CAR-transduced human primary T-cells mixed with (A) human peripheral blood mononuclear cells (PBMC), (B) NSG bone marrow (NSG
BM), and (C) humanized NSG bone marrow (huNSG BM).
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natured and contained higher amounts of extraneous
proteins.
Concentration & purification of the fusion proteins
Forty-eight hours before supernatant harvest, the fusion
protein-expressing clones were cultivated in serum-free
medium, in order to avoid interference of the serum pro-
teins in the purification process. Centricon filters with
30 kDa cut-off were used to concentrate the cell super-
natant, and Protein A Dynabeads were used for purifica-
tion of the fusion proteins, as Protein A binds to the Fc
portion of CD19sIg1-3 and CD19sIg1-4.Product characterization
From calculations based on the amino acid sequences
alone, the fusion proteins CD19sIg1-3 and CD19sIg1-4
should have molecular masses respectively of 47 kDa and
57 kDa. Figure 1B shows a reduced SDS-PAGE electro-
phoresis gel with the fusion proteins isolated from produ-
cer cell supernatants, confirming expected findings.
Depending on the pH of the eluate from the Protein A
Dynabeads purification process, the fusion proteins were
isolated in the presence or absence of denaturing condi-
tions. Denatured samples were kept at pH 2.8 and native
samples had their pH re-adjusted to 7.5 immediately fol-
lowing non-denaturing elution. Figure 1C shows a non-
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Figure 3 Evaluation of CD19sIg1-4 fusion protein for detection of anti-CD19 CAR-modified primary human T-cells. Flow cytometry plots
demonstrating the sensitivity of detection of anti-CD19 CAR-transduced human primary T-cells mixed in increasing numbers of non-transduced
(NT) T-cells using FITC-conjugated anti-IgG Fc F(ab’)2 fragment (FITC-anti-IgG Fc, upper panels) or Alexa Fluor 488-labeled CD19sIg1-4
(AF488-CD19sIg1-4, lower panels).
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influence the fusion protein mobility on SDS-PAGE
(unlike sample reduction, data not shown), but affected
the functional assays, as shown on Figure 1D. However,
in addition to the expected monomer-sized band ob-
served on Figure 1B, the majority of the protein is larger
and in which likely represents glycosylated or dimeric
forms, slowing the mobility on the gel.
ELISA assays
ELISA assays were used to assess the presence of neces-
sary CD19 epitopes on the CD19sIg1-3 and CD19sIg1-4
fusion proteins, using as a capture antibody the murine
monoclonal FMC63 (Figure 1D), the same monoclonal
antibody used for development of most of the CD19-
specific CAR constructs currently used in clinical trials
[11]. CD19sIg1-3 presented minimal binding, and only
CD19sIg1-4 showed FMC63 specific binding, in both de-
natured and native forms. To further investigate the CD19
epitopes on CD19sIg1-4, different antibodies targeting the
human CD19 molecule were analyzed by ELISA as cap-
ture antibodies (HIB19, F-3 and 2E2B6B10). As a control,
antibodies targeting human CD20 and prostate-specific
membrane antigen (PSMA), two previously published tar-
gets of CAR, were also evaluated against CD19sIg1-4
(Figure 1E). As expected, the anti-CD20 and anti-PSMA
antibodies did not demonstrate any binding of the
CD19sIg1-4 fusion protein, and FMC63 and HIB19 bound
to CD19sIg1-4 in a dose-dependent fashion. F-3 and
2E2B6B10 did not bind to the fusion protein. F-3 is an
antibody directed to the C-terminus, absent in the fusion
protein, and 2E2B6B10 is an antibody developed against
full-length recombinant human CD19, recommended for
immunohistochemistry, ELISA, Western Blot, but notflow cytometry, therefore most likely also targeting the C-
terminus. These results present evidence that the binding
sites of the FMC63 and HIB19 antibodies are the extracel-
lular domains (N-terminus) of the human CD19 protein
present, at least in part, in CD19sIg1-4.Flow cytometry staining using fusion proteins
The isolated fusion protein CD19sIg1-4 was conjugated to
Alexa Fluor 488 and used to detect Jurkat cells transduced
to stably express CD19-specific CAR by flow cytometry
(data not shown). To investigate the ability of the reagent
to specifically detect CD19-specific CAR-expressing pri-
mary human cells and to evaluate the presence of undesir-
able non-specific background staining, mixtures of cells
were prepared for flow cytometry acquisitions. These in-
cluded CAR-positive primary human T-cells mixed with
normal donor human PBMC (Figure 2A), murine NSG
marrow (Figure 2B) and “humanized” NSG marrow from
NSG mice engrafted with human CD34(+) cells (Figure 2C).
Acquisition gating strategies were purposely broad in order
to evaluate the heterogeneous cell populations, and not just
lymphocytes. In each experiment, samples stained with the
labeled fusion protein presented distinct homogeneous
staining of CAR-modified cells, with less background stain-
ing than the FITC-conjugated anti-IgG Fc F(ab’)2 fragment.
In Figure 2C, non-specific binding of FITC-anti-IgG Fc F
(ab’)2 fragment to “humanized” NSG marrow cells required
gate adjustment in order to allow proper detection of CAR-
modified cells. Labeled CD19sIg1-4 was a reliable reagent
for the detection of CD19-specific CAR-modified cells, with
minimal binding to human PBMC, and virtually no binding
to murine or humanized murine bone marrow cells, unlike
the FITC-conjugated anti-IgG Fc F(ab’)2 fragment.
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protein CD19sIg1-4, T-cells were activated from PBMC
and transduced with a lentiviral vector carrying a CD19-
specific CAR derived from the FMC63 monoclonal anti-
body [12]. CAR-transduced populations of T-cells with
75% of anti-CD19 CAR expression were mixed with in-
creasing numbers of non-transduced (NT) T-cells, creat-
ing a range of percentages of CAR-modified T-cells
between 0.5 and 75%, and those cell mixes were stained
with either FITC-conjugated anti-IgG Fc F(ab’)2 fragment
(Figure 3, upper panels) or Alexa Fluor 488-labeled
CD19sIg1-4 (Figure 3, lower panels). The efficiency of(A) FITC-F(ab’)2 anti-human IgG1 Fcγ

















(C) CD19sIg1-4  fusion protein
5%CAR+ T-cellsnon-transduced
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Figure 4 Comparison of CD19sIg1-4 fusion protein to similar commer
human T-cells, non-transduced and 5% CAR-transduced, using FITC-conjug
Protein L (B), Alexa Fluor 488-labeled CD19sIg1-4 (C) and Alexa Fluor 488-l
cell population after pre-incubation of Alexa Fluor 488-labeled CD19sIg1-4detection of CAR-expressing cells with CD19sIg1-4 was
similar to the detection using FITC-conjugated F(ab’)2
fragment goat anti-human IgG1 Fcγ. Detection with la-
beled CD19sIg1-4 was reliable even with as low as 0.5%
of modified cells, a level of detection below what is
needed for efficacy in immunotherapy models. Detection
of CD19-specific CAR-transduced cells revealed MFI for
FITC-conjugated F(ab’)2 anti-IgG1 Fcγ of 15,065 and MFI
for Alexa Fluor 488-labeled CD19sIg1-4 of 2,848, at similar
detection rates. The decreased MFI with the CD19sIg1-4
protein may be due to the heterogeneous labeling of the fu-
sion protein with Alexa Fluor 488. Another possible(B) biotinylated Protein L 













(D) CD19-Fc fusion protein
5%CAR+ T-cellsnon-transduced
5%CAR+ T-cells
cially available reagents. Flow cytometry plots of staining of primary
ated F(ab’)2 fragment goat anti-human IgG1 Fcγ(A), biotinylated
abeled rhCD19-Fc fusion protein (D). E. Results of staining of the same
with anti-CD19 monoclonal antibody FMC63.
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of anti-CD19 CAR is lower than the binding of the FITC-
conjugated F(ab’)2 anti-IgG1 Fcγ.
In order to evaluate the performance of CD19sIg1-4
against other similar commercially available reagents, anti-
CD19 CAR-positive primary human T-cells at expected
frequency of 5% mixed with non-transduced T-cells were
stained with Alexa Fluor 488-labeled CD19sIg1-4, Alexa Fluor
488-labeled rhCD19-Fc fusion protein (ACROBiosystems),
biotinylated Protein L (GenScript) and FITC-conjugated
F(ab’)2 fragment goat anti-human IgG1 Fcγ (Figure 4).
Staining of the cell population by FITC-conjugated F(ab’)2
anti-IgG1 Fcγ was once again the brightest, with mean de-
tection of 6.8% CAR-modified cells. Biotinylated Protein L
presented mean detection of 6.4% of cells, while CD19sIg1-
4 had mean detection of 4.8%, compared to 1.6% by the
CD19-Fc fusion protein from ACROBiosystems. Similarly
to previous results, significant staining background was ob-
served after staining with FITC-conjugated F(ab’)2 anti-
IgG1 Fcγ and Protein L (demonstrated on non-transduced
T-cells panels on Figure 4A and 4B). Both CD19sIg1-4 and
CD19-Fc fusion proteins labeled with Alexa Fluor 488
presented similar MFI (Figure 4C and 4D).
To provide further evidence of specific binding, CD19
blocking experiments were performed using anti-human
CD19 monoclonal antibody FMC63. Alexa Fluor 488-
labeled CD19sIg1-4 (40 ng/μl) was mixed with FMC63
(500 ng/μl) at 12.5 : 1 ratio and incubated for 1 hour at
4°C before being added to staining tubes. The flow cy-
tometry results demonstrated a 70% detection decrease
(Figure 4E, from 4.8% to 1.5%), confirming that the
binding of CD19sIg1-4 to CAR-modified cells is specific-
ally mediated by anti-CD19 and CD19 interaction.
Discussion
The fusion protein CD19sIg1-4 presented higher binding
to the anti-CD19 monoclonal antibody FMC63 than
CD19sIg1-3 (Figure 1D), and for this reason it was chosen
for progression into the next series of experiments. The
exons 2 and 4 of the human CD19 gene code for two C2-
type immunoglobulin-like domains, separated by a small
intervening domain coded in exon 3; we hypothesize that
the absence of exon 4 in the CD19sIg1-3 construct may
have affected the final protein structure and epitope recog-
nition by FMC63. CD19sIg1-4 also avidly bound to other
anti-CD19 monoclonal antibodies, and did not bind to
monoclonal antibodies specific to other antigens, further
demonstrating evidence that the human CD19 molecule
was present in its structure. The binding of CD19sIg1-4 to
Protein A also demonstrates that Fc domains (that bind to
Protein A) are constitutively present in the fusion protein.
The detection specificity of labeled CD19sIg1-4 was
evident even in complex cell mixtures (Figures 2A-C).
Previously published studies on flow cytometric detectionof CAR expression have routinely used enriched T-cell
populations, minimizing staining background. Comparative
staining using same population of anti-CD19 CAR-
transduced T-cells with CD19sIg1-4 against other com-
mercially available reagents, biotinylated Protein L,
CD19-Fc fusion protein, and FITC-conjugated F(ab’)2
fragment goat anti-human IgG1 Fc, demonstrated con-
sistent and sensitive detection of CAR-modified T-cells
(Figures 3 and 4) with less non-specific staining. The
commercially available CD19-Fc fusion protein
(ACROBiosystems) differs from CD19sIg1-4 as it does
not contain all of exon 1 and contains part of exon 5;
we hypothesize the detection performance of that re-
agent may have been impaired by distinct epitope pat-
tern, by distinct polymerization, by the labeling
procedure with Alexa Fluor 488, or a combination of
all. Commonly used alternative approaches, such as
anti-human IgG1 Fc or biotinylated Protein L, present
significant background and limited discrimination. Pro-
tein L presents the need of secondary staining with labeled
streptavidin, with additional protocol steps and potential
cell loss. The findings described here provide evidence
of superior performance of the labeled fusion protein
CD19sIg1-4 in detecting CD19-specific CAR-positive cells,
even in complex cell populations, as found in common ex-
perimental situations for evaluation of CAR-mediated cyto-
toxicity in tumor immunotherapy models and clinical trials.
Conclusions
A fusion protein containing the extracellular domain of the
human CD19 molecule fused to IgG1Fc was developed
and stably produced and secreted by a modified cell line.
CD19sIg1-4 was recognized by two α-CD19 antibodies and
bound specifically by CD19-specific CAR-expressing cells.
Detection of CD19-specific CAR-expressing cells by the
CD19sIg1-4 fusion protein was very sensitive (detecting
populations as low as 0.5%) and specific, superior to cur-
rently commercially available CD19-Fc fusion protein, and
comparable to standard detection with FITC-conjugated
F(ab’)2 fragment goat anti-human IgG1 Fcγ and biotinylated
Protein L, with reduced background staining when used in
samples containing primary hematopoietic cells.
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